New use permitted: FDA approves latanoprost as first-line IOP reducer

February 1, 2003

Peapack, NJ-Pharmacia Ophthalmology will begin making its latanoprost ophthalmic solution(Xalatan) available for initial treatment of elevated eye pressure associated with open-angle glaucoma or ocular hypertension.